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Activation of a TLR9 mediated 
innate immune response in 
preeclampsia
Rachel D. Williamson1, Fergus P. McCarthy1, Louise C. Kenny1,3 & Cathal M. McCarthy1,2
Preeclampsia is a multisystemic disorder leading to the development of a placental ischemic 
microenvironment with a resultant increase in oxidative stress. There is evidence that mitochondrial 
dysfunction and the innate immune system both play a role in the pathophysiology of this disease. 
Mitochondrial DAMPs such as mtDNA bind specific pattern recognition receptors such as Toll-like 
receptor 9 (TLR9) on the endosomal surface of immune cells, in particular neutrophils, subsequently 
activating them and triggering an innate response. We hypothesised that the exaggerated innate 
immune response seen in preeclampsia is provoked by dysfunctional mitochondria. Here we provide 
evidence that TLR9 activity is significantly increased at time of disease in women with preeclampsia. 
Furthermore, we show activation of neutrophil markers, Calprotectin, Myeloperoxidase (MPO), and IL-8 
are significantly increased at time of disease compared to uncomplicated pregnancies. This research 
supports a potential role of TLR9 activation of an innate immune response evident in preeclampsia 
which may possibly be initially triggered by dysfunctional mitochondria.
Preeclampsia is multifactorial disorder of pregnancy that is defined by the onset of hypertension and protein-
uria after 20 weeks’ gestation. One of the most established characteristics of this disorder is the inability of the 
trophoblasts to invade the maternal uterine decidual arteries, resulting in poor placentation. Production of pla-
cental anti-angiogenic factors such as soluble fms-related tyrosine kinase 1 (sFlt-1) and soluble endoglin (sEng) 
have been extensively researched in pre-eclampsia1,2. More recently, the cardiovascular system and its role in 
the development of preeclampsia is being explored3. Other pathological characteristics of preeclampsia include 
placental and systemic oxidative stress and dysfunction of the maternal vasculature4,5. In normal pregnancies 
there is evidence of a controlled systemic inflammatory response where cytokines promote the infiltration of the 
spiral arteries by invading trophoblast cells6. This controlled inflammatory response becomes dysregulated in 
preeclampsia resulting in abnormal activation of monocytes, neutrophils and the endothelium causing maternal 
inflammation7. There is overwhelming evidence that oxidative stress plays a key role in the pathophysiology of 
preeclampsia8,9. In turn oxidative stress, as a result of a placental ischemic microenvironment, releases reactive 
oxygen species into the maternal circulation, which can provoke a systemic inflammatory response10. The innate 
immune system acts as both a protector and effector during pregnancy. The innate system encompasses neutro-
phils, dendritic cells, natural killer cells and macrophages and these immune responders are activated to protect 
the mother from pathogens. Toll-like receptors (TLRs) are a family of type I transmembrane pattern recognition 
receptors (PRRs) that identify invading pathogens or endogenous damage signals and instigate an innate immune 
response. TLR9 can detect conserved sequences known as pathogen-associated molecular patterns (PAMPs) and 
also specifically respond to endogenous molecular structures known as damage-associated molecular patterns 
(DAMPs) via unmethylated CpG dinucleotide motifs as evident on mitochondrial DNA11. Activation of endo-
somal TLR9 involves an intracytoplasmic signalling cascade that leads to the up-regulation of pro-inflammatory 
transcription factors and subsequent liberation of pro-inflammatory cytokines12. There is evidence of increased 
TLR9 expression in both placental tissue and peripheral blood mononuclear cells (PBMC) from patients with 
preeclampsia compared with controls13,14.
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Neutrophils are short-lived effector cells of the innate immune system. These immune cells are activated in 
women during pregnancy and are further stimulated in preeclampsia15. Histopathological evidence has shown 
extensive infiltration of neutrophils in the systemic vasculature of women with preeclampsia compared to 
controls16,17. Neutrophils express a number of TLR’s on their surface including TLR918. Mitochondrial DNA 
(mtDNA) has been shown to activate neutrophils via a TLR9 signalling cascade, which elicits a neutrophil 
pro-inflammatory phenotype19–21. Neutrophil activation results in the secretion of a number of markers including 
reactive oxygen species (ROS), matrix metalloproteinase-8 (MMP-8), calprotectin, myeloperoxidase (MPO) and 
the pro-inflammatory cytokine IL-822.
Our research has previously provided evidence of a role for mitochondrial dysfunction in the pathophysiology 
of preeclampsia with an increase in ΔmtDNA evident between 15 and 20 weeks in women with preeclampsia23. 
Interestingly we also showed a significant increase in mtDNA at time of disease (TOD) in women with preec-
lampsia compared to controls24. The aim of this study was to investigate if the increase in mtDNA we previously 
reported in preeclampsia triggers activation of TLR9 signalling cascade. We also wanted to determine if a subse-
quent neutrophil pro-inflammatory phenotype was elicited in preeclampsia compared to controls by measuring a 
number of neutrophil activation markers longitudinally in pregnancy. We hypothesised that dysfunctional mito-
chondria provokes an exaggerated innate immune response in preeclampsia.
Results
Determination of TLR9 activity and downstream markers of neutrophil activation at 15 weeks’ 
gestation. To determine if TLR9 was activated by circulating mediators present in preeclampsia, HEK-TLR9 
cells were treated with 3% plasma. The level of neutrophil activation markers, calprotectin, MPO, MMP8 and 
IL-8 were also examined. Firstly, there was no significant increase in TLR9 activity at 15 weeks’ gestation in cases 
compared to controls (0.28 ± 0.02 v 0.2 ± 0.02; P = 0.99) (Fig. 1a). We subsequently measured a number of well 
described markers of neutrophil activation in both study groups at 15 weeks’ gestation. There was no signifi-
cant increase in calprotectin (1319 ng/ml ± 87.96, v 1198 ng/ml ± 56.76; P = 0.23) (Fig. 1b) or myeloperoxidase 
(Median [IQR]: 6.72 ng/ml [2.20–13.13] v 4.83 ng/ml [2.11–8.41]; P = 0.14) between cases and controls (Fig. 1c). 
There was also no significant difference in MMP8 (1041.27 pg/ml ± 42.96 v 1075.62 pg/ml ± 88.24; P = 0.69) 
(Fig. 1d) or the pro-inflammatory cytokine IL-8 (median [IQR]: 8.99 [3.32–30.70] v 9.32 [2.18–29.85]; P = 0.95) 
between cases and controls at 15 weeks’ gestation (Fig. 1e).
Determination of TLR9 activity and downstream markers of neutrophil activation at 20 weeks’ 
gestation. There was no significant increase in TLR9 activity at 20 weeks’ gestation in cases compared to 
controls (0.29 ± 0.01, v 0.30 ± 0.02; P = 0.88) (Fig. 2a). While there was no change in the levels of calprotectin 
between cases and controls at 20 weeks’ gestation (1155 ng/ml ± 68.45 v 1234 ng/ml ± 61.10; P = 0.42) (Fig. 2b), 
there was a significant increase in myeloperoxidase in cases compared to controls (Median [IQR]: 5.02 ng/ml 
[2.36–9.08] v 7.07 ng/ml [2.74–17.24]; P = 0.02) (Fig. 2c). There was no significant change in the levels of MMP8 
between cases and controls (1116.73 pg/ml ± 48.24 v 1053.74 pg/ml ± 54.05; P = 0.41) (Fig. 2d). There was no 
significant increase in IL-8 in cases compared to controls at 20 weeks’ gestation (Median [IQR]: 7.95 pg/ml [2.52–
30.31] v 13.49 pg/ml [3.66–46.66]; P = 0.14) (Fig. 2e).
Activation of TLR9 activity provokes a neutrophil-derived pro-inflammatory phenotype at time 
of disease in preeclampsia. There was a significant increase in TLR9 activity at TOD in preeclampsia 
cases compared to controls (0.29 ± 0.01 v 0.35 ± 0.01; P = 0.01) (Fig. 3a). Subsequently, there was also a signif-
icant increase in both calprotectin (1946.55 ng/ml ± 155.08 v 1516.45 ng/ml ± 145.84; P = 0.04) (Fig. 3b) and 
Figure 1. TLR9 activity and downstream markers of neutrophil activation did not alter at 15 weeks’ gestation. 
There was no significant increase in TLR9 activity (a) or neutrophil activation markers Calprotectin (b), MPO, 
(c) MMP-8 (d) and IL-8 (e) at 15 weeks’ gestation between cases and controls.
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myeloperoxidase (Median [IQR]: 8.33 ng/ml [5.70–14.20] v 4.52 ng/ml [3.53–8.73]; P = 0.01) (Fig. 3c) respec-
tively at TOD in cases compared to controls. There was no significant increase in MMP-8 in cases when com-
pared with controls at time of TOD, (842.92 pg/ml ± 87.07 v 1140.64 pg/ml ± 144.77; P = 0.08) (Fig. 3d). Finally, 
there was a significant increase in the pro-inflammatory cytokine IL-8 (Median [IQR]: 6.13 pg/ml [1.18–28.68] v 
24.63 pg/ml [5.37–71.20]; P = 0.01) at TOD in cases compared to controls (Fig. 3e).
Evidence of elevated innate immune response across gestation in preeclampsia. We investi-
gated if the neutrophil-mediated innate immune response were altered longitudinally in pregnancy. Initially, 
there was no difference in TLR9 activity across gestation in controls. (Fig. 4a). Similarly, there was no significant 
change in calprotectin, MPO and IL-8 expression in controls (Fig. 4b,c,e). MMP-8 was significantly decreased in 
uncomplicated pregnancies (Fig. 4d).
In cases complicated with preeclampsia, both TLR9 and calprotectin were significantly increased across 
gestation (0.28 ± 0.02, 0.30 ± 0.02, 0.37 ± 0.02; P = 0.01) and (1318.69 ng/ml ± 87.95, 1233.77 ng/ml ± 68.45, 
Figure 2. TLR9 activity and downstream markers of neutrophil activation did not alter at 20 weeks’ gestation. 
There was no significant increase in TLR9 activity (a) or neutrophil activation markers Calprotectin (b), MMP-8 
(d) and IL-8 (e) at 20 weeks’ gestation between cases and controls. MPO expression (c) is significantly increased 
in cases compared with controls (P = 0.02).
Figure 3. Circulating plasma mediators activate a TRL9-mediated innate immune response in preeclampsia at 
TOD. TLR-9 activity (a), Calprotectin (b), MPO (c), and IL-8 (e) are significantly increased at time of disease 
in cases compared to controls (P = 0.01). There was no significant increase in MMP-8 at TOD in cases in 
comparison to controls.
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1946.55 ng/ml ± 145.84; P = 0.0001) respectively. (Fig. 5a,b). There was no significant increase in MPO, (6.72 ng/
ml [2.20–13.13], 7.09 ng/ml [2.74–17.24], 8.33 ng/ml [5.70–14.20]; P = 0.14), MMP-8 (1075.62 pg/ml ± 88.24, 
1053.74 pg/ml ± 54.05, 1140.64 pg/ml ± 87.08; P = 0.82) or IL-8 (9.32 pg/ml [2.18–29.85], 13.49 pg/ml [3.66–
46.66], and 24.63 pg/ml [5.37–71.20]; P = 0.13) across gestation in preeclampsia cases (Fig. 5c–e).
Determination of TLR9 activity and downstream markers of neutrophil activation in preterm 
cases versus term cases. We next explored if there was a difference in the neutrophil pro-inflammatory 
phenotype across all time-points in women who developed preeclampsia and delivered either before 37 weeks or 
after 37 weeks’ gestation (Table 1). There was no significant difference in TLR9 activity in preterm preeclampsia 
compared to term preeclampsia across gestation. Similarly, there was no statistical significance at each time-point 
when comparing expression of calprotectin, MPO and MMP8 in preterm preeclampsia versus term preeclampsia. 
Interestingly IL-8 expression is initially increased at 15 weeks’ gestation in women who developed preterm preec-
lampsia, but the cytokine levels reduce as pregnancy progresses.
Figure 4. Normal pregnancy did not activate a TLR9 mediated innate immune response. There was no 
significant increase in TLR9 activity (a), Calprotectin (b), MPO (c) in healthy control pregnancies across 
gestation. MMP8 (d) is significantly reduced at term pregnancies (P = 0.01), while IL-8 (e) showed no 
significant difference across gestation in healthy control pregnancies.
Figure 5. Neutrophil activation markers are increased across pregnancyin preeclampsia. TLR9 activity (a), 
Calprotectin (b), are both significantly increased across gestation in cases with preeclampsia (P = 0.01). There 
was no significant increase in neutrophil activation markers MPO (c), MMP8 (d) and IL-8 (e) across gestation 
in cases with preeclampsia.
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Discussion
Pregnancy is associated with a maternal systemic inflammatory response; however, this response is exaggerated in 
preeclampsia. There has been a number of studies which have provided evidence of increased neutrophil activa-
tion in women with preeclampsia16,25,26. In this present study, we investigated if circulating mediators (including 
mtDNA)23, trigger TLR9 activity with the subsequent downstream activation of a neutrophil-mediated innate 
immune response in women with preeclampsia and healthy controls. We showed TLR9 activity is significantly 
increased in women with preeclampsia compared to healthy controls at time of disease. There was a correspond-
ing increase in production of downstream neutrophil activation markers, calprotectin, myeloperoxidase, MMP8 
and the pro-inflammatory cytokine IL-8 in women with preeclampsia compared to healthy controls at time of 
disease, indicating that complete activation of neutrophil pro-inflammatory phenotype only became evident late 
in pregnancy in preeclampsia.
The innate immune response plays a well described role in the pathophysiology of preeclampsia. 
Mitochondrial DAMPs such as mtDNA bind specific pattern recognition receptors such as TLR9 on the endo-
somal surface of the immune cells, in particular, neutrophils and activate an innate response. TLR9 receptors are 
also localised to trophoblasts and the villous stromal vascular endothelium and their expression is increased in 
preeclampsia13. We have shown a significant increase in TLR9 activity using a reporter cell assay incubated with 
plasma taken at time of disease in preeclampsia cases compared to healthy controls. Furthermore, previous work 
in our lab using the same study group samples examined mtDNA (as a marker of mitochondrial dysfunction) 
and reported that mtDNA was also significantly increased at time of disease in preeclampsia cases in the same 
study cohort23. This indicates that the increase in mitochondrial DAMP (mtDNA) at time of disease may activate 
a TLR9 mediated innate immune response in preeclampsia cases only. Exciting new work by He et al. has iden-
tified an additional role for TLR9 in preeclampsia where they established that TLR9 supressed angiogenesis in 
part by increasing sFlt-1 expression in a murine model of preeclampsia27. Furthermore, research carried out in 
spontaneous hypertensive rats, illustrated circulating mtDNA may lead to the activation of the innate immune 
system through TLR921. Research by Goulopoulou et al., has also shown preliminary data indicating that TLR9 
activation provokes preeclampsia–like symptoms in pregnant rats20 emphasising the pathogenic role of TLR9 in 
preeclampsia.
Calprotectin is a calcium binding protein and is located in the cytosol of neutrophils and is released upon neu-
trophil activation. In our study, calprotectin was significantly increased at time of disease compared to controls. 
This is in agreement with recent studies which have reported increase in calprotectin at term in preeclampsia26. 
Akçum et al., reported increased circulating calprotectin levels at term in women with preeclampsia, and inter-
estingly found an additional increase in women with severe preeclampsia.
MPO is a lysosomal enzyme mainly produced and released by activated neutrophils. In this study, we showed 
a significant increase in MPO in cases as early as 20 weeks’ gestation when compared with controls and this 
significant increase was equally evident at time of disease in preeclampsia. Previous studies measuring MPO in 
preeclampsia have reported conflicting results; some studies have reported no difference in MPO in preeclampsia 
in samples taken at 24 weeks or later in the third trimester28,29, whereas Gandley et al., reported a 3-fold increase 
in circulating MPO levels in women with preeclampsia compared to matched healthy controls at 32–38 weeks’ 
gestation30. The variation in MPO levels in previous preeclampsia studies may be due to small sample size. In 
our study we compared 60 cases and 120 matched controls, which to our knowledge is one of the biggest studies 
carried out in relation to MPO and preeclampsia.
MMP8 is part of the MMP family which consists of 23 zinc and calcium dependent proteases that effect differ-
ent mechanisms of the extracellular matrix. In recent years, MMPs have become a target of interest in preeclamp-
sia due to its role in vascular function and remodelling31,32. Recent research shows strong evidence that MMP8 
play an important role in mediating endothelial cell angiogenesis32. Furthermore, endothelial dysfunction is a 
pathogenic characteristic of preeclampsia, dysregulated MMP8 expression may play a crucial role in the disrup-
tion of angiogenesis in preeclampsia leading to endothelial dysfunction. In our study, there was an increase in 
circulating levels of MMP8 expression at TOD in women with preeclampsia cases compared to healthy controls.
Cytokines and chemokines have been extensively studied as markers of inflammation involved in the patho-
physiology of preeclampsia. In this study, we showed a significant increase in circulating IL-8 levels at time of 
disease in cases compared to controls. IL-8 has previously shown to be increased in women with preeclampsia 
Neutrophil markers
15 weeks 
(Preterm N = 19)
15 weeks 
(Term N = 38) P Value
20 weeks 
(Preterm N = 19)
20 weeks 
(Term N = 37) P Value
TOD  
(Preterm N = 6)
TOD (Term 
N = 16) P Value
TLR9 Signal 0.31 ± 0.05 0.27 ± 0.03 0.66 0.30 ± 0.06 0.29 ± 0.03 0.41 0.37 ± 0.03 0.39 ± 0.04 0.713
Calprotectin (ng/ml) 1043.15 ng/ml ± 126.19
1645.66 ng/
ml ± 187.30 0.16
886.99 ± ng/ml 
245.48
1167.96 ng/
ml ± 77.80 0.57
1878.35 ng/
ml ± 424.90
2055.57 ng/
ml ± 170.62 0.77
MPO (ng/ml) 4.42 ng/ml [1.77–10.25]
6.58 ng/ml 
[2.11–9.70] 0.56
4.55 ng/ml 
[2.48–8.74]
6.15 ng/ml 
[2.96–21.46] 0.84
8.59 ng/ml 
[4.72–11.87]
8.33 ng/ml 
[5.67–14.78] 0.43
MMP8 (pg/ml) 1138.41 pg/ml ± 149.24
989.38 pg/
ml ± 113.31 0.25
1097.48 pg/
ml ± 108.58
1098.46 pg/
ml ± 88.69 0.97
1775.73 pg/
ml ± 466.30
1263.75 pg/
ml ± 182.92 0.12
IL-8 (pg/ml) 32.09 pg/ml [7.40–192.91]
8.12 pg/ml 
[2.19–18.25] 0.17
22.92 pg/ml 
[4.76–188.69]
12.67 pg/ml 
[2.11–18.23] 0.32
24.63 pg/ml 
[2.68–47.59]
24.63 pg/ml 
[9.78–75.14] 0.81
Table 1. Plasma levels of TLR9 activity, neutrophil activation markers and pro-inflammatory cytokine IL-8 in 
patients with preterm and term preeclampsia. Data is presented as mean ± SEM and median (25–75 percentiles) 
where applicable.
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in the third trimester33. A recent study reported a significant increase in IL-8 in early gestation (5–15 weeks’) in 
women who subsequently went on to develop preeclampsia. However, a limitation of their study was the small 
sample size (n = 9)34. Other studies investigating IL-8 throughout pregnancy reported similar results to ours with 
no significant increase evident in the second trimester35,36 but a significant increase in IL-8 is evident in the third 
trimester in women with preeclampsia compared to healthy controls37.
Preterm preeclampsia occurs before 37 weeks’ gestation and is frequently regarded as a slightly different phe-
notype to preeclampsia occurring at term. Therefore, we investigated whether neutrophil activation triggers an 
altered innate immune response in preterm preeclampsia compared to term preeclampsia. In this study, there 
was no statistically significant difference in the concentration of neutrophil activation makers in preterm versus 
term in our cohort.
When investigating the activation of a TLR9 mediated innate immune response across pregnancy, there was 
no significant difference in expression of any of the neutrophil markers measured in healthy controls. However, in 
preeclampsia, significant increases were seen in neutrophil activation markers, TLR9 and calprotectin, illustrating 
that the innate immune response may be initially triggered earlier in preeclampsia but complete activation is not 
significantly evident until later in pregnancy. This is in agreement with recent studies of maternal inflammation 
(cytokines such as IL-6, TNF-α) in preeclampsia, whereby low level inflammation is evident early in pregnancies 
but is amplified in the third trimester of pregnancy38–40. This current study shows that the TLR9 activation of the 
innate immune system may play a role in the pathophysiology of preeclampsia in late gestation.
Conclusion
Here we provide evidence that circulating plasma mediators may activate a TRL9-mediated innate immune 
response in preeclampsia. We show that the activity of TLR9, a receptor for mtDNA, is significantly increased 
at time of disease in preeclampsia. Subsequently we have shown increased production of neutrophil activation 
markers particularly late in pregnancy in preeclampsia. Finally, we have shown that possible activation of TLR-9 
by dysfunctional mitochondria may provoke an exaggerated neutrophil-mediated innate immune response in 
preeclampsia.
Material and Methods
Study subjects. Subjects were recruited from the Screening for Pregnancy Endpoints (SCOPE) study Ireland 
which is an international multicentre prospective cohort study of nulliparous singleton pregnancies aimed to 
develop a screening test to predict adverse pregnancy outcomes including preeclampsia, SGA infants and spon-
taneous pre-term birth41,42. A nested case-control study within SCOPE Ireland was conducted which included all 
preeclampsia cases in SCOPE Ireland and matched controls with a case-to-control ratio of 1:2. Preeclampsia cases 
was defined as a systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg on at least two 
occasions 4 hrs apart after 20 weeks’ gestation and with proteinuria (24 hour urinary protein ≥300 mg or urine 
dipstick protein ≥+2). Randomly selected controls were taken from healthy pregnant women who had uncom-
plicated pregnancies which were defined as pregnancies not affected by preeclampsia, preterm birth or growth 
restriction and delivered at >37 weeks. All blood pressure readings were <140 and/or <90 mmHg prior to the 
onset of labour. These were matched with the cases for maternal age, body mass index (BMI) and gestational 
age. Both 15 and 20 week samples were taken from the SCOPE study from women who subsequently went onto 
develop preeclampsia (n = 60) and controls (n = 120). Samples were also taken from a subset of women (n = 25) 
at the time of disease (TOD) with preeclampsia and matched controls. The 60 women with preeclampsia were 
composed of 39 women who developed term preeclampsia and 21 preterm preeclampsia cases. The SCOPE study 
was conducted according to the guidelines laid down in the Declaration of Helsinki, and all the procedures were 
approved by the Clinical Research Ethics Committee of the Cork Teaching (EMC5(10)05/02/08), and all women 
provided written informed consent.
Sample collection. Plasma samples were collected in BD Heparin Vacutainer tubes, placed on ice, and cen-
trifuged at 2,400 g for 10 minutes at 4 °C according to a standardised protocol. Plasma samples were stored at 
−80 °C until analysis.
TLR-9 activity. TLR9 ligand activity was monitored with HEK-blue TLR9 Reporter Cell assay (InvivoGen). 
All experiments were performed using a cell density of 50,000 cells in a 96 well plate. Cells were initially seeded 
and left overnight prior to treatment for 24 hrs with 3% plasma taken at 15 and 20 weeks’ gestation (cases, n = 60, 
controls, n = 120) and TOD (cases, n = 25, controls, n = 25). The supernatant was incubated with Quanti-Blue 
detection medium (InvivoGen) and the activity was read on a Varioskan Flash plate reader (Thermo Scientific) 
at 630 nm.
Calprotectin analysis. Plasma calprotectin (S100A8/S100A9) concentrations were measured by 
enzyme-linked immunosorbent assay (ELISA) using human S100A8/S100A9 Quantikine kit. Heparin plasma 
samples from all time-points were initially diluted a 100-fold in assay buffer and then directly added to a 
pre-coated plate. The ELISA was performed as per manufacturers’ instructions.
Myeloperoxidase, MMP8, IL-8 analysis. Myeloperoxidase (MPO), Matrix metalloproteinases-8 
(MMP8) and interleukin-8 (IL-8) concentrations were measured respectively at all time-points by individual 
ELISA DuoSet kits (R&D SYSTEMS. USA & Canada). ELISA was carried out as per manufacturer’s instructions.
Statistical analysis. Analysis was performed using GraphPad Prism. Data were presented using median 
(±Interquartile range [IQR]) and comparisons of data between cases and controls were performed using a 
non-parametric Mann Whitney U test or Wilcoxon signed rank test as appropriate when data was not normally 
7Scientific RepoRts |          (2019) 9:5920  | https://doi.org/10.1038/s41598-019-42551-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
distributed. Data that was normally distributed were represented as mean (±SEM) and comparisons of data 
between cases and controls were performed using an unpaired t-test. P values < 0.05 were considered as statisti-
cally significant.
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